Literature DB >> 16315304

High dose intravenous immunoglobulin treatment: mechanisms of action.

Peter Boros1, Gabriel Gondolesi, Jonathan S Bromberg.   

Abstract

Intravenous immunoglobulin (IVIg) treatment was introduced as replacement therapy for patients with antibody deficiencies, but evidence suggests that a wide range of immune-mediated conditions could benefit from IVIg. The immunoglobulins are precipitated from human plasma by fractionation methods. In conclusion, the differences in basic fractionation methods and the addition of various modifications for purification, stabilization, and virus inactivation result in products significantly different from each other.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315304     DOI: 10.1002/lt.20594

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

2.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

Review 3.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

4.  The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?

Authors:  Alexandra James; Roslyn B Mannon
Journal:  Curr Transplant Rep       Date:  2015-06-01

Review 5.  Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.

Authors:  Ralph S Shapiro; Richard L Wasserman; Vincent Bonagura; Sudhir Gupta
Journal:  J Clin Immunol       Date:  2014-01-30       Impact factor: 8.317

6.  A 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxis.

Authors:  Seunghoon Han; Gun Hyung Na; Dong-Goo Kim
Journal:  Drug Des Devel Ther       Date:  2017-07-11       Impact factor: 4.162

7.  Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis.

Authors:  Chun-Yu Yen; Miao-Chiu Hung; Ying-Chi Wong; Chia-Yuan Chang; Chou-Cheng Lai; Keh-Gong Wu
Journal:  Sci Rep       Date:  2019-07-18       Impact factor: 4.379

Review 8.  Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action.

Authors:  Teiji Sawa; Mao Kinoshita; Keita Inoue; Junya Ohara; Kiyoshi Moriyama
Journal:  Antibodies (Basel)       Date:  2019-11-03

Review 9.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

10.  The Possible Role of IVIG in the Treatment of Atrial Fibrillation Accompanied by Fulminant Myocarditis in a 12-Year-Old Pediatric Patient.

Authors:  Can Yilmaz Yozgat; Osman Yesilbas; Selcuk Uzuner; Nigar Bayramova; Gokce Ergun; Lala Nurmammadova; Eser Tekin; Hafize Otcu Temur; Yilmaz Yozgat
Journal:  Case Rep Pediatr       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.